Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Endocrine 1

Conditions

Lymphoma, T-Cell, Peripheral 20Lymphoma, T-Cell, Cutaneous 19Lymphoma, T-Cell 17Lymphoma 16Lymphoma, Large B-Cell, Diffuse 9Leukemia, Lymphocytic, Chronic, B-Cell 9Mycosis Fungoides 8Lymphoma, Large-Cell, Anaplastic 8Multiple Myeloma 7Lymphoma, Non-Hodgkin 7Hodgkin Disease 7Lymphoma, Mantle-Cell 6Lymphoma, Follicular 6Lymphoma, B-Cell, Marginal Zone 5Immunoblastic Lymphadenopathy 5Burkitt Lymphoma 5Breast Neoplasms 5Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Neoplasms 4Neoplasm Metastasis 4Leukemia, Myeloid, Acute 4Leukemia 4Urinary Bladder Neoplasms 3Prostatic Neoplasms 3Pancreatic Neoplasms 3Lymphoma, Extranodal NK-T-Cell 3Lung Neoplasms 3Hematologic Neoplasms 3

Interventions

Everolimus 5Octreotide 4Leucovorin 4Temozolomide 3Oxaliplatin 3Fluorouracil 3Capecitabine 3vatalanib 2temsirolimus 2Trastuzumab 2Sirolimus 2Melphalan 2Irinotecan 2Biological Therapy 2Bevacizumab 2tipifarnib 1romidepsin 1regorafenib 1pentetreotide 1pazopanib 1napabucasin 1motesanib diphosphate 1irinotecan sucrosofate 1folfirinox 1cixutumumab 1batifiban 1antineoplaston AS 2-1 1antineoplaston A10 1Vinorelbine 1Thalidomide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Islet Cell × romidepsin × Clear all
NCT00084461 2013-06-04

Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors

National Cancer Institute (NCI)

Phase 2 Terminated
25 enrolled
Endocrine

Glucagonoma, Insulinoma, Somatostatinoma, Gastrinoma, Carcinoma, Islet Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡